spacer
home > pmps > winter 2003 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

As PMPS passes its five year milestone may I welcome you to this Winter 2003 issue. So much has happened in the world of pharmaceutical manufacturing since the first issue in 1998, especially with the gathering pace of outsourcing. I'm delighted to be able to look back with a sense of pride at how much has been achieved, while looking forward to the next five years with anticipation. PMPS has kept in tune with developments as the market has steadily grown, with an increase in the number of contract manufacturing organisations (CMOs), business transactions and the number of employees working in the sector. The type of contract business has also diversified, with a trend towards an increase in the outsourcing of development activities needed to get products to market

faster. I say there has been a steady growth because it would be a gross exaggeration to suggest a growth rate of the market for development outsourcing of 25 per cent per year.

Figures of that magnitude, plucked out of thin air create unrealistic expectations and do little to enhance the reputation of this sector. For example, we have seen what happened with biotech when unfulfilled predictions turned sour. I'm conscious of a painful recession in biotech as sentiment plunged from the heady days of the market in 2000, driven as it was by so much hyperbole. Nevertheless, I remain optimistic about outsourcing as we look forward to the next Bio/PharMOS event with an exhibition and conference for manufacturing outsourcing services on 23rd-25th March 2004.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Editor of PMPS, Patricia Lobo rounds up current issues impacting on development and manufacturing in biotech and pharma.
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Joanne Glover
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PharmaFluidics awarded VLAIO research grant

Ghent, Belgium – June 2, 2020 PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO). The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement